来源|贝多商业&贝多财经9月15日,轩竹生物科技股份有限公司-B(下称“轩竹生物”)通过港交所上市聆讯,并披露了聆讯后资料集(即招股书)。据贝多商业&贝多财经了解,轩竹生物曾计划在A股上市,但未能成行。具体而言,轩竹生物曾于2022年在上海证券交易所递交招股书,报考在科创板上市,原计划募资24.70亿元。2023年3月,轩竹生物上会但被暂缓审议。2024年5月,该公司及其保荐人中金公司撤回发行上市...
Source Link来源|贝多商业&贝多财经9月15日,轩竹生物科技股份有限公司-B(下称“轩竹生物”)通过港交所上市聆讯,并披露了聆讯后资料集(即招股书)。据贝多商业&贝多财经了解,轩竹生物曾计划在A股上市,但未能成行。具体而言,轩竹生物曾于2022年在上海证券交易所递交招股书,报考在科创板上市,原计划募资24.70亿元。2023年3月,轩竹生物上会但被暂缓审议。2024年5月,该公司及其保荐人中金公司撤回发行上市...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.